AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Blood

• Publication date

  2015-09-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2014-12-618900PMID 26116659PMCID PMC4559932
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

  2015cited by this paper
• Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

  2014influential reference
• Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).

  2014cited by this paper
• Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.

  2014cited by this paper
• The bone marrow niche for haematopoietic stem cells

  2014cited by this paper
• A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.

  2014influential reference
• Declining childhood and adolescent cancer mortality

  2014cited by this paper
• Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate

  2014cited by this paper
• Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors.

  2014cited by this paper
• Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment

  2012cited by this paper
• Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts

  2012cited by this paper
• The molecular basis of T cell acute lymphoblastic leukemia.

  2012cited by this paper
• Regulation of Aldo–Keto Reductases in Human Diseases

  2012cited by this paper
• Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia

  2012cited by this paper
• Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy.

  2012cited by this paper
• A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

  2011cited by this paper
• Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program

  2011influential reference
• Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

  2011cited by this paper
• A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity

  2011cited by this paper
• Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104

  2011influential reference
• Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance.

  2011cited by this paper
• Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

  2010cited by this paper
• The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

  2010influential reference
• Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches.

  2010cited by this paper
• A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

  2010cited by this paper
• The hematopoietic stem cell niche: Low in oxygen but a nice place to be

  2010cited by this paper
• Steroid Hormone Transforming Aldo‐Keto Reductases and Cancer

  2009cited by this paper
• The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.

  2009cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Severe Hypoxia Defines Heterogeneity and Selects Highly Immature Progenitors Within Clonal Erythroleukemia Cells

  2007cited by this paper
• Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.

  2007cited by this paper
• Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

  2007cited by this paper
• Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia

  2007cited by this paper
• The pediatric preclinical testing program: Description of models and early testing results

  2007cited by this paper
• Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms.

  2007cited by this paper
• Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.

  2006cited by this paper
• Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

  2006cited by this paper
• Treatment of acute lymphoblastic leukemia.

  2006cited by this paper
• Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia

  2006cited by this paper
• Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.

  2004cited by this paper
• Therapeutic Synergy of Oral Taxane BMS-275183 and Cetuximab versus Human Tumor Xenografts

  2004cited by this paper
• The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.

  2003cited by this paper
• Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

  2003influential reference
• The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse.

  2002cited by this paper
• Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models.

  2001cited by this paper
• Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones

  2000cited by this paper
• Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.

  2000cited by this paper
• Cancer statistics

  1989cited by this paper
• Chinese Journal of Cancer

  year unknowncited by this paper

• Emerging small-molecule AKR1C3 inhibitors development for cancer therapy: Progress from 2021 to 2025.

  2025cites this paper
• AKR1C3 enhances radioresistance in esophageal adenocarcinoma via inhibiting ferroptosis through suppressing TRIM21-mediated ubiquitination of HSPA5

  2025cites this paper
• Tumor Microenvironment: Current Understanding and Therapeutic Implications in Adult and Pediatric Cancers

  2025cites this paper
• The Relationship between AKR1C3 and Diseases

  2025cites this paper
• AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies

  2024cites this paper
• Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies

  2024cites this paper
• IN VIVO ACTIVITY OF THE SECOND-GENERATION PROTEASOME INHIBITOR IXAZOMIB AGAINST PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS.

  2024cites this paper
• The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia

  2024cites this paper
• Lessons learned from 20 years of preclinical testing in pediatric cancers

  2024cites this paper
• Possible New Histological Prognostic Index for Large B-Cell Lymphoma

  2023influential citation
• A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma

  2023cites this paper
• A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma.

  2023cites this paper
• Nitroreduction: A Critical Metabolic Pathway for Drugs, Environmental Pollutants, and Explosives.

  2022cites this paper
• Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3

  2022cites this paper
• AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker

  2022cites this paper
• The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies

  2021cites this paper
• Acute Leukemias

  2021cites this paper
• AKR1C3 Expression in T and B Acute Lymphoblastic Leukemia/Lymphoma for Clinical Use as a Biomarker

  2021cites this paper
• A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.

  2021cites this paper
• Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy

  2021cites this paper
• Therapeutic Targeting of the Leukaemia Microenvironment

  2021cites this paper
• Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.

  2021cites this paper
• A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma

  2020cites this paper
• An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL

  2020influential citation
• Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.

  2020cites this paper
• Overview of AKR1C3: Inhibitor Achievements and Disease Insights.

  2020cites this paper
• Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors

  2020cites this paper
• Management of Relapsed and Refractory ALL

  2020cites this paper
• Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020.

  2020cites this paper
• Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells

  2020cites this paper
• Identification and validation of AKR1C1/2/3 as hepatocellular carcinoma risk modules via an integrated strategy

  2020cites this paper
• Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

  2019cites this paper
• Characterization of a highly specific monoclonal antibody against human aldo‐keto reductase AKR1C3

  2019cites this paper
• Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs.

  2019cites this paper
• OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

  2019influential citation
• Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia.

  2019cites this paper
• The treatment of adolescents and young adults with acute lymphoblastic leukemia

  2019cites this paper
• Hypoxia-targeted drug delivery.

  2019cites this paper
• Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.

  2019cites this paper
• AKR1C enzymes sustain therapy resistance in paediatric T-ALL

  2018cites this paper
• Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome

  2018cites this paper
• Drug‐DNA adducts as biomarkers for metabolic activation of the nitro‐aromatic nitrogen mustard prodrug PR‐104A

  2018cites this paper
• Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL

  2017cites this paper
• DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A

  2017cites this paper
• Discovery of the hypoxia-activated prodrug SN30000

  2017cites this paper
• The Use of Pediatric Patient-Derived Xenografts for Identifying Novel Agents and Combinations

  2017cites this paper
• Patient-Derived Mouse Models of Cancer

  2017cites this paper
• Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy

  2017cites this paper
• Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

  2016cites this paper
• Hypoxia-activated prodrugs: paths forward in the era of personalised medicine

  2016cites this paper
• MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation

  2016cites this paper
• Cell intrinsic and extrinsic regulation of leukemia cell metabolism

  2016cites this paper
• Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

  2016cites this paper
• Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.

  2016cites this paper
• A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program

  2016cites this paper
• A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts

  2016cites this paper
• Hypoxia-Sensitive Materials for Biomedical Applications

  2016cites this paper
• Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs

  2016cites this paper
• Identifying novel therapeutic agents using xenograft models of pediatric cancer

  2016cites this paper
• Biomarker of sensitivity to PR-104 in leukemia.

  2015cites this paper